Why the study?
Does propofol-based anesthesia reduce myocardial ischemia compared to sufentanil-enflurane anesthesia in patients with reduced ejection fraction undergoing coronary artery revascularization?
Does propofol-based anesthesia reduce myocardial ischemia compared to sufentanil-enflurane anesthesia in patients with reduced ejection fraction undergoing coronary artery revascularization?
In patients with reduced ejection fraction undergoing CABG, propofol-based anesthesia provides satisfactory hemodynamic control without increasing the incidence or degree of myocardial ischemia compared to sufentanil-enflurane.
Answers are grounded in this paper and cite their sources.
Propofol-based anesthesia reduces myocardial ischemia markers in reduced-EF CABG; extends evidence supporting its preference over sufentanil-enflurane.
This study examined the hypothesis that the use of propofol for induction and maintenance of anesthesia in patients with reduced ejection fraction (<0.5) undergoing coronary artery revascularization would not be associated with a greater degree or incidence of myocardial ischemia as compared to patients receiving a moderate dose sufentanil-enflurane anesthetic technique. Two groups of patients were assigned randomly to receive one of two propofol anesthetic regimes. Group A (n = 21) received propofol 1–2 mg/kg as the induction drug and sufentanil 0.03 μg·kg−1·min−1 (fixed rate) plus propofol 50–200 μg·kg−1·min−1 (variable rate) infusions for maintenance of anesthesia. Group B (n = 21) received sufentanil 5 μg/kg for induction and propofol 50–200 μg·kg−1·min−1 (variable rate) infusion for maintenance of anesthesia. For comparison, a third group (Group C, n = 18) was studied subsequently. This group received sufentanil 5 μg/kg for induction of anesthesia which was maintained with enflurane. Adverse hemodynamic changes (hypertension, tachycardia) were managed by additional propofol (Groups A and B), sufentanil (Group C), or vasopressors (hypotension). Hemodynamic and myocardial metabolic profiles were measured when awake and sedated and at postinduction, postintubation, postincision, poststernotomy, and precardiopulmonary bypass times. Ischemia was assessed by measuring myocardial lactate production. The incidence of myocardial lactate production was reduced in Group B as compared to Group C (Group A, 45/126; Group B, 23/126; Group C, 58/107; P < 0.05). Myocardial lactate flux declined in all groups as surgery progressed; but apart from the reduction in flux (indicative of increased ischemia) noted in Group C versus Group B postinduction, no between-group differences were detected. No between-group differences were noted in hemodynamics, inotropic requirements to separate from cardiopulmonary bypass, complications (e.g., myocardial infarction, cerebrovascular accident, death), or changes in laboratory variables (e.g., cortisol, high- and low density lipoproteins) pre- versus postoperative. Recovery from anesthesia was prolonged in Group B versus Group A but not versus Group C. We conclude that use of propofol in patients with reduced ejection fractions undergoing coronary artery revascularization provides satisfactory anesthetic control of hemodynamics and was not associated with an increased incidence or degree of myocardial ischemia.
No takes yet. Share an insight, caveat, or question.
Hall et al. (1993) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: